Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALBIREO PHARMA, INC.

(ALBO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Albireo to Present at Upcoming Investor Conferences

11/10/2021 | 08:31am EST

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company’s management team will be presenting at the following investor conferences:

  • Jefferies London Healthcare Conference
    Wednesday, November 17 at 11:20 a.m. GMT / 6:20 a.m. ET
  • Piper Sandler 33rd Annual Virtual Healthcare Conference
    A pre-recorded fireside chat will be available on-demand beginning on Monday, November 22 at 10:00 a.m. ET

The webcasts of the presentations will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the live Jefferies webcast, it is recommended that users register at least 15 minutes prior to the scheduled start times. An archived version of the webcasts will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for 30 days following the event.

About Albireo
Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireo’s lead product, Bylvay™ (odevixibat), was approved by the U.S. FDA as the first drug for the treatment of pruritus in patients 3 months of age and older in all types of progressive familial intrahepatic cholestasis (PFIC), and it is also being developed to treat other rare pediatric cholestatic liver diseases with Phase 3 trials in Alagille syndrome and biliary atresia, as well as an Open-label Extension (OLE) study for PFIC. In Europe, Bylvay has been approved for the treatment of PFIC in patients 6 months or older and has been submitted for pricing and reimbursement approval. The Company is progressing a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies moving ahead with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2019 and 2020 Best Places to Work in Massachusetts. For more information on Albireo, please visit www.albireopharma.com.

Media Contact:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lauren Sneider, 857-300-1737, lauren.sneider@albireopharma.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578


Primary Logo

Source: Albireo Pharma, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about ALBIREO PHARMA, INC.
01/06Albireo Increases 2021 Bylvay (odevixibat) Sales Guidance
AQ
01/05ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K/A
PU
01/05ALBIREO PHARMA, INC. Results of Operations and Financial Condition, Change in Director..
AQ
01/05Albireo Increases 2021 Bylvay™á(odevixibat) Sales Guidance
AQ
01/05Albireo Pharma, Inc. Provides Sales Guidance for the Full Year of 2021
CI
01/05ALBIREO PHARMA, INC. : Results of Operations and Financial Condition, Change in Directors ..
AQ
01/05ALBIREO PHARMA : Increases 2021 BylvayTM (odevixibat) Sales Guidance - Form 8-K
PU
01/05Albireo Pharma, Inc. Announces Resignation of Roger A. Jeffs as Independent Director
CI
01/03Immix Biopharma Shares More Than Double on FDA Designation
DJ
2021Albireo Pharma's Early Stage Trial Confirms Safety, Tolerability of Liver Disease Drug
MT
More news
Analyst Recommendations on ALBIREO PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 18,3 M - -
Net income 2021 -66,2 M - -
Net cash 2021 209 M - -
P/E ratio 2021 -7,97x
Yield 2021 -
Capitalization 526 M 526 M -
EV / Sales 2021 17,4x
EV / Sales 2022 7,75x
Nbr of Employees 90
Free-Float 87,2%
Chart ALBIREO PHARMA, INC.
Duration : Period :
Albireo Pharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALBIREO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 27,30 $
Average target price 73,33 $
Spread / Average Target 169%
EPS Revisions
Managers and Directors
Ronald H. W. Cooper President, Chief Executive Officer & Director
Simon John Harford Chief Financial Officer & Treasurer
David John Chiswell Chairman
Jan Peter Mattsson Chief Scientific Officer, Managing Director-Sweden
Joan Connolly Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ALBIREO PHARMA, INC.17.22%526
GILEAD SCIENCES, INC.-5.16%86 377
REGENERON PHARMACEUTICALS-1.05%65 339
VERTEX PHARMACEUTICALS10.66%61 849
WUXI APPTEC CO., LTD.-11.62%47 600
BIONTECH SE-37.08%39 180